Literature DB >> 26990138

Persistent Multiyear Control of Relapsed T-Cell Acute Lymphoblastic Leukemia With Successive Donor Lymphocyte Infusions: A Case Report.

Jeffrey S Huo1, Heather J Symons1, Nancy Robey1, Michael J Borowitz2, Eric S Schafer3, Allen R Chen1.   

Abstract

There are few therapeutic options for patients with T-cell acute lymphoblastic leukemia (T-ALL) who have recurrent disease after initial matched sibling hematopoietic stem cell transplantation. While a second hematopoietic stem cell transplant (HSCT) from a haploidentical donor offers the conceptual possibility of greater graft versus leukemia effect, there is minimal literature to describe the efficacy of this approach in recurrent pediatric T-ALL. We present the case of a now 9-year-old female in whom second haploidentical HSCT, followed by successive donor lymphocyte infusions in response to minimal residual disease reemergence, has led to 3+ years of ongoing disease control without graft versus host disease and excellent quality of life.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  T-cell acute lymphoblastic leukemia; donor lymphocyte infusion; haploidentical bone marrow transplant; relapse

Mesh:

Year:  2016        PMID: 26990138      PMCID: PMC4877254          DOI: 10.1002/pbc.25971

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  13 in total

1.  Feasibility of treating post-transplantation minimal residual disease in children with acute leukemia.

Authors:  Nirali N Shah; Michael J Borowitz; Nancy C Robey; Christopher J Gamper; Heather J Symons; David M Loeb; Alan S Wayne; Allen R Chen
Journal:  Biol Blood Marrow Transplant       Date:  2014-03-27       Impact factor: 5.742

2.  High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia.

Authors:  David Wu; Anna Sherwood; Jonathan R Fromm; Stuart S Winter; Kimberly P Dunsmore; Mignon L Loh; Harvey A Greisman; Daniel E Sabath; Brent L Wood; Harlan Robins
Journal:  Sci Transl Med       Date:  2012-05-16       Impact factor: 17.956

3.  Outcome of children and adolescents with a second or third relapse of acute lymphoblastic leukemia (ALL): a population-based analysis of the Austrian ALL-BFM (Berlin-Frankfurt-Münster) study group.

Authors:  Bettina Reismüller; Christina Peters; Michael N Dworzak; Ulrike Pötschger; Christian Urban; Bernhard Meister; Klaus Schmitt; Karin Dieckmann; Helmut Gadner; Andishe Attarbaschi; Georg Mann
Journal:  J Pediatr Hematol Oncol       Date:  2013-07       Impact factor: 1.289

4.  Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.

Authors:  Shannon R McCurdy; Jennifer A Kanakry; Margaret M Showel; Hua-Ling Tsai; Javier Bolaños-Meade; Gary L Rosner; Christopher G Kanakry; Karlo Perica; Heather J Symons; Robert A Brodsky; Douglas E Gladstone; Carol Ann Huff; Keith W Pratz; Gabrielle T Prince; Amy E Dezern; Ivana Gojo; William H Matsui; Ivan Borrello; Michael A McDevitt; Lode J Swinnen; B Douglas Smith; Mark J Levis; Richard F Ambinder; Leo Luznik; Richard J Jones; Ephraim J Fuchs; Yvette L Kasamon
Journal:  Blood       Date:  2015-03-26       Impact factor: 22.113

5.  A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies.

Authors:  Maksim Mamonkin; Rayne H Rouce; Haruko Tashiro; Malcolm K Brenner
Journal:  Blood       Date:  2015-06-08       Impact factor: 22.113

6.  Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434.

Authors:  Stuart S Winter; Kimberly P Dunsmore; Meenakshi Devidas; Nancy Eisenberg; Barbara L Asselin; Brent L Wood; Marcia S Leonard Rn; John Murphy; Julie M Gastier-Foster; Andrew J Carroll; Nyla A Heerema; Mignon L Loh; Elizabeth A Raetz; Naomi J Winick; William L Carroll; Stephen P Hunger
Journal:  Pediatr Blood Cancer       Date:  2015-03-08       Impact factor: 3.167

7.  Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation.

Authors:  Heather J Symons; M Sue Leffell; Nancy D Rossiter; Marianna Zahurak; Richard J Jones; Ephraim J Fuchs
Journal:  Biol Blood Marrow Transplant       Date:  2009-12-02       Impact factor: 5.742

8.  HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation.

Authors:  Amer M Zeidan; Patrick M Forde; Heather Symons; Allen Chen; B Douglas Smith; Keith Pratz; Hetty Carraway; Douglas E Gladstone; Ephraim J Fuchs; Leo Luznik; Richard J Jones; Javier Bolaños-Meade
Journal:  Biol Blood Marrow Transplant       Date:  2013-12-01       Impact factor: 5.742

9.  Superiority of preemptive donor lymphocyte infusion based on minimal residual disease in acute leukemia patients after allogeneic hematopoietic stem cell transplantation.

Authors:  Yamin Tan; Kaili Du; Yi Luo; Jimin Shi; Ling Cao; Yanlong Zheng; Gaofeng Zheng; Yanmin Zhao; Xiujing Ye; Zhen Cai; He Huang
Journal:  Transfusion       Date:  2013-12-23       Impact factor: 3.157

10.  Impact of minimal residual disease, detected by flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia.

Authors:  Merav Bar; Brent L Wood; Jerald P Radich; Kristine C Doney; Ann E Woolfrey; Colleen Delaney; Frederick R Appelbaum; Ted A Gooley
Journal:  Leuk Res Treatment       Date:  2014-03-23
View more
  3 in total

Review 1.  Adoptive Cell Therapy for Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.

Authors:  Premal D Lulla; Maksim Mamonkin; Malcolm K Brenner
Journal:  Cancer J       Date:  2019 May/Jun       Impact factor: 3.360

2.  Tumor Talk and Child Well-Being: Perceptions of "Good" and "Bad" News Among Parents of Children With Advanced Cancer.

Authors:  Angela M Feraco; Veronica Dussel; Liliana Orellana; Tammy I Kang; J Russell Geyer; Abby R Rosenberg; Chris Feudtner; Joanne Wolfe
Journal:  J Pain Symptom Manage       Date:  2017-01-03       Impact factor: 3.612

3.  Persistent donor derived Vδ4 T cell clones may improve survival for recurrent T cell acute lymphoblastic leukemia after HSCT and DLI.

Authors:  Ling Xu; Jianyu Weng; Xin Huang; Chengwu Zeng; Shaohua Chen; Suxia Geng; Lijian Yang; Suijing Wu; Suming Huang; Xin Du; Yangqiu Li
Journal:  Oncotarget       Date:  2016-07-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.